London, UK – [Insert Date of Publication] – Scancell Holdings plc, a leading immuno-oncology company, has achieved a significant milestone with the authorization of its Phase III clinical trial for iSCIB1+ by the UK Medicines and Healthcare products Regulatory Agency (MHRA). This pivotal, placebo-controlled, double-blind, and randomized study will evaluate the efficacy of Scancell’s novel DNA ImmunoBody, iSCIB1+, in combination with established checkpoint inhibitors, for the treatment of advanced melanoma. The trial is set to enroll 550 participants across approximately 90 sites in Australia, Canada, the European Union, the United Kingdom, and the United States, marking a substantial global undertaking to bring this promising therapeutic candidate closer to patients.
n
The authorization from the MHRA follows a series of crucial regulatory clearances, including the recent acceptance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) in January 2026. This multi-national Phase III trial represents a critical step in the registrational pathway for iSCIB1+, aiming to generate robust data that could support its potential approval for patients battling stage III or IV unresectable melanoma, a life-threatening form of skin cancer.
n
Core Facts: A Global Push for Advanced Melanoma Treatment
n
Scancell Holdings’ iSCIB1+ is poised to enter a new era of clinical evaluation with the commencement of its Phase III trial. The study, now authorized by the UK’s MHRA, is designed as a registrational, double-blind, randomized, and placebo-controlled investigation. It will specifically target patients diagnosed with stage III or IV unresectable melanoma, a population with a significant unmet medical need and limited treatment options.
n
The trial’s ambitious scope is underscored by its international reach, with recruitment planned at around 90 clinical sites strategically located across Australia, Canada, the European Union, the United Kingdom, and the United States. This broad geographical distribution aims to ensure a diverse patient population and accelerate recruitment, a critical factor in the timely completion of large-scale clinical trials.
n
Participants will be randomly assigned in a precise 1:1 ratio to one of two treatment arms. The investigational arm will receive a 8mg dose of iSCIB1+ administered in conjunction with ipilimumab and nivolumab, two widely recognized and effective checkpoint inhibitors. The control arm will receive a placebo, also administered alongside ipilimumab and nivolumab. This design is intended to isolate and definitively measure the added benefit of iSCIB1+ when combined with standard-of-care immunotherapy.
n
The primary objective of this Phase III trial is to evaluate the impact of iSCIB1+ on progression-free survival (PFS). PFS is a key surrogate endpoint in oncology trials, reflecting the duration for which a patient lives without their cancer progressing. The data derived from this primary endpoint are intended to form the basis for a submission seeking accelerated approval from regulatory authorities. Subsequently, overall survival (OS), a measure of how long patients live, will be assessed as a secondary endpoint. Positive OS data would be crucial for supporting an application for full regulatory approval at a later stage, signifying a more definitive demonstration of the drug’s life-extending capabilities.
n
Chronology: A Carefully Orchestrated Path to Phase III
n
The journey of iSCIB1+ from concept to a global Phase III trial has been a meticulously planned and executed process, marked by key regulatory and scientific achievements. The authorization of the Phase III trial by the MHRA is the culmination of extensive preclinical research and promising clinical data from earlier-stage studies.
n
Prior to this pivotal Phase III initiation, Scancell successfully navigated the regulatory landscape in the United States. In January 2026, the company announced the clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). This clearance was a critical prerequisite for commencing clinical trials involving human subjects within the U.S., paving the way for the global recruitment strategy.
n
The design of the current Phase III study has been significantly informed by the outcomes of the preceding Phase II SCOPE trial. This earlier study provided compelling evidence of iSCIB1+’s potential when combined with ipilimumab and nivolumab. In the SCOPE trial, the combination therapy demonstrated a sustained progression-free survival rate of an impressive 77% after 22 months of follow-up. Furthermore, the study reported an overall survival rate of 87.4% at 18 months in the targeted patient population. These encouraging results provided the scientific rationale and statistical power projections necessary to design the larger, more definitive Phase III trial.
n
Scancell anticipates that the Phase III trial will officially commence by the end of 2026. Following the initiation of patient enrollment and treatment, the company has projected that initial data on progression-free survival will be available in the second half of 2028. This timeline, while ambitious, reflects the urgency and strategic importance placed on bringing iSCIB1+ to market.
n
Supporting Data: The Science Behind iSCIB1+
n
At the heart of this advancement lies iSCIB1+, Scancell’s lead product candidate. It is characterized as a deoxyribonucleic acid (DNA) ImmunoBody, a novel therapeutic platform administered via a needle-free intramuscular injection. This administration method is designed to enhance patient compliance and comfort, potentially reducing barriers to treatment.
n
The mechanism of action of iSCIB1+ is rooted in its ability to encode an antibody that specifically targets melanoma-associated antigens. Two key antigens are targeted: gp100 and tyrosinase-related protein 2 (TRP-2). By encoding antibodies against these antigens, iSCIB1+ is designed to stimulate a potent T cell response within the body. These activated T cells are then primed to recognize and attack tumor cells expressing these specific antigens, offering a targeted approach to cancer immunotherapy. This strategy leverages the body’s own immune system to combat the cancer, a hallmark of modern immuno-oncology.
n
The scientific foundation for iSCIB1+ is built upon Scancell’s proprietary ImmunoBody technology, which aims to deliver durable and potent immune responses. The DNA-based nature of the therapy allows for efficient delivery of genetic material encoding the therapeutic antibody, leading to sustained production of the target molecule within the patient.
n
The promising results from the Phase II SCOPE trial serve as the critical supporting data for the current Phase III endeavor. In this earlier study, the combination of iSCIB1+ with ipilimumab and nivolumab not only demonstrated a high PFS rate of 77% at 22 months but also a remarkable OS rate of 87.4% at 18 months. These figures are particularly noteworthy considering the advanced stage of melanoma in the participants, suggesting a significant clinical benefit beyond what might be achieved with current standard-of-care therapies alone. The sustained nature of these responses is also a key indicator of the potential for long-term disease control, a critical goal in the treatment of advanced cancers.
n
Official Responses: Confidence and Strategic Vision
n
The progression of iSCIB1+ to a Phase III trial has been met with considerable optimism and strategic focus from Scancell’s leadership. Dr. Phil L’Huillier, CEO of Scancell, expressed strong confidence in the company’s regulatory trajectory and the significance of this milestone.
n
"Our regulatory strategy continues to build momentum," stated Dr. L’Huillier. "The MHRA CTA for the Phase III trial of our lead asset iSCIB1+ in patients with advanced melanoma is an important milestone bringing us one step closer to delivering iSCIB1+ to patients in a global registrational trial setting."
n
Dr. L’Huillier’s statement highlights the strategic importance of the MHRA’s authorization as a confirmation of the scientific rigor and clinical potential of iSCIB1+. The "momentum" he refers to is evidenced by the parallel progress in securing regulatory approval in the U.S. and the successful design of a large-scale international trial. The phrase "one step closer to delivering iSCIB1+ to patients" underscores the company’s patient-centric mission and its commitment to making this investigational therapy accessible. The emphasis on a "global registrational trial setting" further reinforces the ambition and scale of the undertaking, aiming for broad regulatory acceptance worldwide.
n
It is important to note that iSCIB1+ is currently an investigational product. This means it has not yet received regulatory approval from authorities such as the MHRA, the FDA, or any other global regulatory body for the treatment of melanoma or any other medical condition. Consequently, its safety and efficacy have not yet been definitively established by these agencies. The ongoing Phase III trial is designed precisely to generate the comprehensive data required for such an evaluation.
n
Implications: A New Frontier in Melanoma Treatment and Beyond
n
The advancement of iSCIB1+ to a Phase III trial carries significant implications for the future of advanced melanoma treatment and potentially for other cancers.
n
For Patients with Advanced Melanoma: The most immediate implication is the potential for a new and improved treatment option for patients diagnosed with stage III or IV unresectable melanoma. These individuals often face a grim prognosis, and the availability of novel therapies that can offer durable responses and improved survival rates is paramount. If iSCIB1+ proves successful in the Phase III trial, it could represent a substantial leap forward in their treatment landscape, offering renewed hope and improved quality of life. The needle-free administration could also translate to a better patient experience.
n
For Scancell Holdings: This Phase III trial is a critical inflection point for Scancell. A positive outcome would validate the company’s ImmunoBody technology platform and its therapeutic candidates, potentially leading to significant commercialization opportunities. Success in this trial could attract further investment, partnerships, and accelerate the development of other pipeline assets. Conversely, an unsuccessful outcome could present substantial challenges for the company.
n
For the Field of Immuno-Oncology: The trial’s design, combining a novel DNA ImmunoBody with established checkpoint inhibitors, contributes valuable knowledge to the broader field of immuno-oncology. It explores the potential of synergistic combinations and novel delivery mechanisms to enhance anti-tumor immunity. The success of iSCIB1+ could inspire further research into DNA-based immunotherapies and their application in various cancer types.
n
For Regulatory Pathways: The trial’s objective of supporting accelerated approval based on PFS, with OS data for full approval, reflects a common and efficient regulatory strategy for oncology drugs. Demonstrating its success in this context could set a precedent and further refine how novel immunotherapies are evaluated and brought to market.
n
Potential for Broader Applications: While the current focus is on advanced melanoma, the underlying mechanism of iSCIB1+—stimulating T cell responses against tumor-associated antigens—suggests potential applicability in other cancers that express similar antigens. If successful, future research could explore its use in other melanoma subtypes or different solid tumors, expanding its therapeutic reach.
n
In conclusion, the MHRA’s authorization of Scancell’s Phase III trial for iSCIB1+ marks a pivotal moment in the company’s journey and holds significant promise for the future of advanced melanoma treatment. The extensive global scope of the trial, coupled with the compelling data from earlier studies, positions iSCIB1+ as a strong contender in the ongoing battle against this aggressive disease. The coming years will be crucial in determining whether this investigational therapy can fulfill its potential and bring transformative benefits to patients worldwide.
